
I wanted to invest partially to health and my candidate was $LLY but data proves that bullish trend is not smooth ride for it.
Eli Lilly and Company already had a huge run thanks to drugs like Mounjaro and Zepbound they produced . But expectations are sky high, stock already priced in near-perfect growth, investors' perception is "not bad, could be much more better" even after strong results.
Obesity medication demand is massive , but supply limits and high production costs deaccelerating short-term upside. Competition from Novo Nordisk and money flow into AI/tech stocks are also another factors.
English








